Exosome as the Prognostic and Predictive Biomarker in EBC Patients

N/AActive Not RecruitingNCT05955521

Samsung Medical Center200 enrolled

Overview

This study is the experimental study for serial ctDNA and exosome evaluation in EBC patients

Study Type

INTERVENTIONAL

Allocation

Purpose

SCREENING

Masking

NONE

Enrollment

200

Conditions

Triple Negative Breast Cancer HER2-positive Breast Cancer

Interventions

exosome and ctDNA evaluationPROCEDURE

Serial exosome and ctDNA evaluation during follow up period between neoadjuvant chemotherapy and surveillance after curative surgery.

Eligibility

Sex: FEMALEHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Early breast cancer * Planned neoadjuvant chemotherapy * Triple negative breast cancer or HER2-positive breast cancer Exclusion Criteria: * Stage IV breast cancer * Hormone receptor positive breast cancer

Locations (1)

Ji-Yeon Kim

Seoul, South Korea

Outcomes

Primary Outcomes

Prognostic biomarker for EBC

Positive predictive value of ctDNA/Exosome for BC recurrence

Time frame: 60 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.